In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CardioNet heads for potential $150m IPO (initial public offering):

This article was originally published in Clinica

Executive Summary

Heart monitor developer CardioNet has filed for an initial public offering which the company claims could have a maximum price offering approaching $150m. The San Diego, California-based firm did not disclose the expected number of shares to be offered but did state that it would use the proceeds to pay an outstanding term loan and a success fee connected to the IPO to Silicon Valley Bank. Funds will also be channelled towards increasing sales and marketing capabilities for the company's CardioNet System, which monitors and diagnoses heart rhythm disorders. Over the last three years, the company has cut its net loss considerably, posting a deficit of $6.7m in 2006, down 68% from a loss of $21m in 2004. CardioNet plans to list on the Nasdaq under the ticker symbol "BEAT".

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts